Condition
High Risk Essential Thrombocythemia
Total Trials
2
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
3 treatments under study, led by Peginterferon Alfa2a
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
Phase 2 (1)
Phase 3 (1)
Trial Status
Completed2
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (2)
Showing 2 of 2 trials
NCT01259856Phase 3Completed
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
NCT01259817Phase 2Completed
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
Showing all 2 trials
Research Network
Common Treatments
- Peginterferon Alfa2a2
- Aspirin2
- Hydroxyurea1
Active Sponsors
- Myeloproliferative Disorders-Research Consortium2
- Ronald Hoffman2
- National Cancer Institute (NCI)2
- Roche Pharma AG2
Top Investigators
Icahn School of Medicine at Mount Sinai
Guy's and St Thomas' NHS Foundation Trust
Icahn School of Medicine at Mount Sinai
Hopitaux de Paris
Mayo Clinic
Related Conditions
- High Risk Polycythemia Vera2